An update on strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery: exploiting transformability and bioactivity of PLN and harnessing intracellular lipid transport mechanism.

Expert opinion on drug delivery Pub Date : 2024-02-01 Epub Date: 2024-02-18 DOI:10.1080/17425247.2024.2318459
Taksim Ahmed, Fuh-Ching Franky Liu, Xiao Yu Wu
{"title":"An update on strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery: exploiting transformability and bioactivity of PLN and harnessing intracellular lipid transport mechanism.","authors":"Taksim Ahmed, Fuh-Ching Franky Liu, Xiao Yu Wu","doi":"10.1080/17425247.2024.2318459","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Polymer-lipid hybrid nanoparticle (PLN) is an emerging nanoplatform with distinct properties and functionalities from other nanocarrier systems. PLN can be optimized to overcome various levels of drug delivery barriers to achieve desired therapeutic outcomes via rational selection of polymer and lipid combinations based on a thorough understanding of their properties and interactions with therapeutic agents and biological systems.</p><p><strong>Areas covered: </strong>This review provides an overview of PLN including the motive and history of PLN development, types of PLN, preparation methods, attestations of their versatility, and design strategies to circumvent various barriers for increasing drug delivery accuracy and efficiency. It also highlights recent advances in PLN design including: rationale selection of polymer and lipid components to achieve spatiotemporal drug targeting and multi-targeted cascade drug delivery; utilizing the intracellular lipid transport mechanism for active targeting to desired organelles; and harnessing bioreactive lipids and polymers to magnify therapeutic effects.</p><p><strong>Expert opinion: </strong>A thorough understanding of properties of PLN components and their biofate is important for enhancing disease site targeting, deep tumor tissue penetration, cellular uptake, and intracellular trafficking of PLN. For futuristic PLN development, active lipid transport and dual functions of lipids and polymers as both nanocarrier material and pharmacological agents can be further explored.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"245-278"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2024.2318459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Polymer-lipid hybrid nanoparticle (PLN) is an emerging nanoplatform with distinct properties and functionalities from other nanocarrier systems. PLN can be optimized to overcome various levels of drug delivery barriers to achieve desired therapeutic outcomes via rational selection of polymer and lipid combinations based on a thorough understanding of their properties and interactions with therapeutic agents and biological systems.

Areas covered: This review provides an overview of PLN including the motive and history of PLN development, types of PLN, preparation methods, attestations of their versatility, and design strategies to circumvent various barriers for increasing drug delivery accuracy and efficiency. It also highlights recent advances in PLN design including: rationale selection of polymer and lipid components to achieve spatiotemporal drug targeting and multi-targeted cascade drug delivery; utilizing the intracellular lipid transport mechanism for active targeting to desired organelles; and harnessing bioreactive lipids and polymers to magnify therapeutic effects.

Expert opinion: A thorough understanding of properties of PLN components and their biofate is important for enhancing disease site targeting, deep tumor tissue penetration, cellular uptake, and intracellular trafficking of PLN. For futuristic PLN development, active lipid transport and dual functions of lipids and polymers as both nanocarrier material and pharmacological agents can be further explored.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
优化聚合物-脂质杂化纳米颗粒介导的药物输送策略的最新进展:利用聚合氯化萘的可转化性和生物活性以及细胞内脂质输送机制。
导言:聚合物-脂质混合纳米粒子(PLN)是一种新兴的纳米平台,具有不同于其他纳米载体系统的特性和功能。在充分了解聚合物和脂质的特性以及与治疗剂和生物系统的相互作用的基础上,通过合理选择聚合物和脂质的组合,可以优化 PLN,以克服不同程度的给药障碍,达到理想的治疗效果:本综述概述了聚合氯化萘,包括聚合氯化萘的开发动机和历史、聚合氯化萘的类型、制备方法、其多功能性的证明,以及规避各种障碍以提高给药准确性和效率的设计策略。报告还重点介绍了PLN设计的最新进展,包括:合理选择聚合物和脂质成分,实现时空药物靶向和多靶点级联给药;利用细胞内脂质转运机制,主动靶向所需细胞器;利用生物活性脂质和聚合物放大治疗效果:透彻了解PLN成分及其生物伴侣的特性,对于增强PLN的疾病靶点定位、肿瘤组织深层穿透、细胞摄取和细胞内转运非常重要。为了开发未来的 PLN,可以进一步探索活性脂质运输以及脂质和聚合物作为纳米载体材料和药剂的双重功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
An opinion on advanced cancer immunotherapy through innovations in PD-1 inhibitor delivery systems. Acceptability of Cyltezo pen among biologics autoinjector patients, autoinjector naïve patients, and healthcare professionals. The potential of nanosystems in disrupting adenosine signaling pathways for tumor immunotherapy. How can nanoemulsions be used for photosensitizer drug delivery? Advanced drug delivery strategies for diabetic retinopathy: a comprehensive review on current medications, delivery methods, device innovations, overcoming barriers, and experimental models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1